2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2309

Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Abstract Number: 2310

Increased Risk of Extreme Obesity in Adults with History of Childhood Arthritis
Abstract Number: 2311

Prospective Validation of the Juvenile Spondyloarthritis Disease Activity Index and Its Comparison with Adult Spondyloarthritis Disease Activity Scores
Abstract Number: 2312

Prevalence of Serum 14-3-3η (eta) in Juvenile Idiopathic Arthritis
Abstract Number: 2313

Procalcitonin Differentiates Infection from Active Disease in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 2314

Monoarticular Juvenile Idiopathic Arthritis: A Unique Entity?
Abstract Number: 2315

Symptoms of Depression and Anxiety in Children with JIA: Relation to Other Domains of Health Related Quality of Life
Abstract Number: 2316

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) – a Patient Reported Outcome
Abstract Number: 2317

Knowledge Translation in Juvenile Idiopathic Arthritis in Canada: A Focus on Parents of Children with JIA
Abstract Number: 2318

Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy
Abstract Number: 2319

Bradycardia after High-Dose Solu-Medrol
Abstract Number: 2320

Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years
Abstract Number: 2321

Current Practices and New Directions in Occupational and Physical Therapy for Children with Rheumatic Diseases in the Biologic Era
Abstract Number: 2322

Quantitative Proteomics Comparison of Children with Inactive and Active Uveitis
Abstract Number: 2323

Exploring HLA-DRB1 Risk Alleles in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].